the c-Jun NH 2 -terminal stress-related kinases (13, 16, 17, 19) .
The existence of fibronectin fragments has been documented in chronic inflammatory diseases and shown to be important in the pathogenesis of chronic inflammation, including arthritis and periodontal disease (1, 2, (5) (6) (7) 14, 15) . We generated and characterized several recombinant counterparts of the fibronectin fragments that are found in in vivo conditions (9) . One such fibronectin fragment is defective in binding to heparin. We found that while the native fibronectin molecule promotes growth and attachment of cells, the defective form of the fibronectin fragment triggered cell detachment and showed a proapoptotic effect, since it induced apoptotic cell shape changes and apoptotic cell signaling. Cells treated with this proapoptotic fibronectin fragment showed a decrease in p53 at both the transcriptional and the protein levels (2, (11) (12) (13) 15) .
The transcription factor p53 is a tumor suppressor that plays a critical role in safeguarding the integrity of the genome (20) and controls cell-cycle arrest, apoptosis and cellular senescence (21) . Its expression and activation are tightly controlled within the cell by post-translational modifications, including ubiquitination, acetylation and phosphorylation (22) . Often, p53 regulatory networks are perturbed by stress signals, such as DNA damage, oncogene activation, hypoxia and nitric oxide production, resulting in ubiquitination of p53 (23) and its degradation in the proteasome (24, 25) .
As mentioned above, the reduction in p53 promoter activity and mRNA level in cells exposed to the proapoptotic fibronectin fragment was not sufficient to explain the significant loss of p53 protein. Thus, we hypothesized that the decrease in p53 levels in cells treated with the proapoptotic fibronectin fragment was also due to posttranslational modifications. One of the prevalent modes of p53 downregulation is through its ubiquitination, which targets it to the proteasome for degradation (26) . Currently, there is no literature describing the type of posttranslational modification undergone by p53 that accentuates its degradation in response to inflammation/diseaseassociated extracellular matrix proteins or their fragments. Therefore, this study was initiated to investigate whether fibronectin fragments induce ubiquitination of p53 and its degradation through the proteasome.
Material and methods

Primary periodontal ligament (PDL) cell culture
Human primary PDL cells were isolated and cultured as described (12) . The PDL cells were isolated from the teeth that were extracted from patients undergoing treatment at the School of Dentistry, University of Michigan, Ann Arbor, USA. The donors provided written consent and these were in accordance with the University of Michigan Health Sciences Institutional Review Board. Their use was approved by the University of Michigan Health Sciences Institutional Review Board. Cells were maintained in a-minimal essential medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal calf serum (Hyclone, Logan, UT, USA) and penicillin (100 U/mL) and streptomycin (100 lg/mL).
Recombinant fibronectin proteins
For these studies, we used two previously described recombinant fibronectin fragments (10) that contain the alternatively spliced V region (V + ) and either an intact (H + ) or a mutated, non-functional (H ) ) high-affinity heparin-binding domain. The control fibronectin fragment (CFn), with the intact H + domain, and the proapoptotic fragment (AFn), with the mutated H ) domain, were used at a concentration of 0.1 mM. The proapoptotic fragment is comparable to the diseaseassociated 40 kDa proteolytic fragment, also shown by our group to induce apoptosis in PDL cells.
Western blot analysis
For western blot analysis, cells were lysed in RIPA buffer (Sigma, St Louis, MO, USA) containing protease inhibitors (Sigma). Protein concentration was determined by the BCA protein assay kit (Pierce, Rockford, IL, USA). Equal amounts of protein were resolved by standard procedures using SDS-PAGE with 4-20% gels (Novex; Invitrogen) and electroblotted onto polyvinylidene membranes (PVDF; Immobilon-P; Millipore, Billerica, MA, USA) by semidry transfer blot (Bio-Rad, Hercules, CA, USA) according to the manufacturerÕs instructions. The primary antibodies were mouse anti-human p53-horseradish peroxidase (DO-1), rabbit anti-human ubiquitin and goat antihuman actin (I-19; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Immunoprecipitation
For immunoprecipitation, cells treated with AFn or CFn fragments, or control serum-free medium, in the presence or absence of lactacystin, were lysed in RIPA buffer containing protease inhibitors. Equal amounts of protein from the lysates were precleared with protein G-agarose (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK), incubated with mouse anti-p53 overnight at 4°C and then with protein G-agarose beads for 2 h. After five washes with RIPA buffer, the beads were boiled in SDS-PAGE reducing sample buffer. Supernatants were resolved by SDS-PAGE with 4-20% gels and processed for western blot analysis. After incubation of the PVDF membranes with anti-ubiquitin antibodies, the blots were incubated with Clean Blot HRP reagent (Pierce), which recognized only the native primary antibodies and did not interact with the denatured primary antibodies (IgG) that were used to immunoprecipitate the p53 molecules.
Small interfering RNA (siRNA) transfection experiments
One day before transfection, cells were plated at 60% confluency in six-well dishes. Human ubiquitin UBA52 siRNA (Dharmacon, Thermo Fisher Scientific, Freemont, CA, USA; NM_003333) or the control siRNA (Dharmacon) were introduced into cells using Lipofectamine 2000 (Invitrogen) as recommended by the manufacturer. Thirty-six hours posttransfection, cells were treated with the fibronectin fragments in serum-free medium for 7 h and processed for western blot analysis.
Immunofluorescence
To immunolocalize p53, cells were fixed with 3% paraformaldehyde in phosphate-buffered saline, pH 7.2, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline for 20 min and incubated in 5% bovine serum albumin in Tris Buffered Saline Tween (TBST) (25 mM Tris, 150 mM NaCl, 0.05% Tween-20) for 1 h at room temperature. Cells were then incubated with mouse anti-p53 (DO-1) overnight at 4°C, washed with TBST, treated with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody for 1 h at room temperature and washed with TBST. Then cells were stained with 4¢,6¢-diamidino-2-phenylindole (DAPI; Sigma) for 10 min, rinsed with calcium-and magnesium-free phosphate-buffered saline, air dried, mounted on glass slides with Vectashield (Vector Laboratories, Burlingame, CA, USA), and examined with a Nikon TS100 photomicroscope.
Apoptosis ELISA assay
Cells were pretreated with lactacystin and then treated with proapoptotic or control fibronectin fragment or control media. Thereafter, the cells were lysed, and equal amounts of cell lysate protein were processed to quantify apoptosis using the Cell Death Detection ELISA PLUS kit (Roche, Mannheim, Germany) as recommended by the manufacturer.
Other reagents
The proteasomal inhibitors, lactacystin and MG132, were from Calbiochem (La Jolla, CA, USA). All other chemicals were from Sigma unless mentioned otherwise.
Results
A fragmented fibronectin matrix triggers p53 degradation through a proteasomal pathway
In our previous studies, we observed that a recombinant fibronectin fragment, which is comparable to its in vivo proteolytic counterpart found in inflammatory gingival crevicular fluids, causes a decrease in p53 levels as part of a unique apoptosis pathway. However, only part of the reduction in p53 levels could be explained by transcriptional downregulation (11) , suggesting that other protein degradation pathways, such as the lysosomal and proteasomal pathways (27, 28) , may be contributing to the elimination of p53 when cells are treated with the proapoptotic fibronectin fragment (AFn). First, we pre-incubated PDL cells with different lysosomal enzyme inhibitors before treating cells with the AFn and then examined the cell lysates for p53 protein levels by western blot analysis. As seen in Fig 1A, pretreatment of cells with lysosomal enzyme inhibitors failed to prevent p53 degradation in response to treatment with AFn (lanes 3-12), suggesting that p53 was not being degraded through the lysosomal pathway. Moreover, p53 was also degraded (Fig. 1A , lane 14) in cells pretreated with cycloheximide, a protein synthesis inhibitor, suggesting that new protein synthesis is not required for the degradation of p53 in this pathway.
In addition to the lysosome, the proteasome is an important component of the cell machinery that mediates protein degradation. Protein degradation is vital for initiating, terminating and regulating many cellular processes, and the proteasome is involved in this degradation process. One of the most important regulatory proteins in the cell is p53, and its level is tightly regulated by transcriptional and post-translational modifications (21) . In many an instance, the degradation of p53 in cells is mediated by the proteasome (22) . Therefore, to ascertain whether the degradation of p53 in response to AFn was mediated by the proteasome, we pretreated cells with MG132, a proteasome inhibitor, before treating the cells with AFn. First, we determined that 30 nM was the optimal concentration of MG132, which on its own did not induce cellular toxicity (Fig. 1B, lane 4) . Thereafter, we pretreated cells with 30 nM MG132 for 2 h prior to treating them with AFn for a further 7 h. We observed that inhibiting the proteasome with MG132 prevented the degradation of endogenous p53 in response to AFn (Fig. 1C , lanes 2 and 5). Control medium or a control fibronectin fragment (CFn) did not alter the p53 levels (Fig. 1C, lanes 1  and 3) . From these experiments, we concluded that the degradation of p53 in cells treated with the AFn is mediated through the proteasome. In earlier studies (9, 11-13), we showed that primary PDL cells underwent apoptosis when treated with AFn. We observed that cells overexpressing p53 were less susceptible to apoptosis. Since, in this present study (Fig. 1) we observed that inhibition of the proteasome resulted in stabilization of p53, we tested whether this approach could be used as an alternative to overexpressing p53 to rescue the cells from apoptosis. Indeed, pretreatment of cells with MG132 prior to exposure of cells to the AFn prevented cell rounding, nuclear condensation and fragmentation, the hallmarks of apoptosis (11; Fig. 2A ). There were also strong nuclear signals for p53 in cells that were pretreated with proteasome inhibitor and incubated with the AFn. This showed that primary cells could resist apoptosis induced by the AFn if the proteasomal degradation of p53 was halted. In fact, clinical trials testing proteasome inhibitors have shown that this may be a viable treatment for chronic inflammation (29) (30) (31) .
To further show that proteasome inhibitors, by virtue of their ability to inhibit the degradation of endogenous p53, can rescue cells from apoptosis, we pretreated cells with lactacystin, another proteasomal inhibitor, and measured the fold change in apoptosis in cells exposed to AFn. As shown in Fig. 2B , apoptosis, measured by an ELISA assay, which measures cytoplasmic histone-associated DNA fragments, was substantially reduced by the pretreatment of cells with lactacystin.
Downregulation of p53 by a fragmented fibronectin matrix is mediated by ubiquitination
Prior to degradation, p53 undergoes ubiquitination (24) , and in cells treated with proteasomal inhibitors, such as MG132 or lactacystin, there is an accumulation of multi-ubiquitinated p53 molecules. In further experiments, pretreatment of cells with the proteasome inhibitor lactacystin also stabilized p53 and prevented its degradation (Fig. 3A, lanes 4, 5 and 6 ). In the absence of lactacystin, cells treated with the AFn had lower levels of p53 (Fig. 3A, lane 4) . Since treatment with a proteasomal inhibitor can result in the accumulation of multi-ubiquitinated p53 molecules, we examined this possibility in our system. We immunoprecipitated the proteins shown in Fig. 3A with an anti-p53 antibody and probed them with an antibody to ubiquitin. We observed a ladder of bands in cells pretreated with lactacystin, and these were, in fact, different ubiquitinated forms of p53, since they were recognized by an anti-ubiquitin antibody after immunoprecipitating them with an anti-p53 antibody. Furthermore, cells that were treated with AFn and lactacystin had more ubiquitinated p53 forms (Fig. 3B, lane 3) than the cells treated with lactacystin alone (Fig. 3B, lane 4) . From the preceding experiments, it was clear that the major site for the degradation of p53 in cells, which were exposed to AFn, was the proteasome (Figs. 1)3) . When destined for degradation, p53 gets ubiquitinated, and ubiquitinated p53 is a substrate for the proteasome (20, 22, (32) (33) (34) . We had also observed the presence of ubiquitinated p53 in cells that were treated with proteasome inhibitor and AFn. Therefore, to confirm the participation of ubiquitin in the degradation of p53 induced by AFn, we transfected cells with siRNA for ubiquitin. As seen in Fig. 4A , ubiquitin expression was significantly reduced in cells transfected with ubiquitin siRNA (Fig. 4A,  lane 3) . Next, cells were transfected with ubiquitin siRNA and then treated with the AFn (Fig. 4B) . In cells transfected with ubiquitin siRNA, there was less ubiquitination of p53 and consequently higher levels of p53 (Fig. 4B , lane 2) compared with cells that were treated with the control siRNA (Fig. 4B, lane 1) . Moreover, cells with suppressed levels of ubiquitin had higher levels of p53 even in the presence of AFn (Fig. 4B, lane 4) compared with cells transfected with a control siRNA (Fig. 4B, lane 3) , indi- cating that ubiquitination of p53 is important for its degradation in this process. In addition to mitigating the degradation of p53 mediated by AFn, inhibition of ubiquitin expression also blocked the apoptosis of cells initiated by AFn, as shown in Fig. 4C . The residual apoptosis seen in ubiquitin siRNA transfected cells in the presence of AFn might be attributed to the remaining low level of ubiquitin expression that was observed in these cells (Fig. 4A, lane 3) .
Discussion
The ECM is composed of several macromolecules, which play an important role in development, Our results showing that proapoptotic fibronectin fragment-induced p53 degradation is ubiquitin dependent are in agreement with previous findings. In these reports, ubiquitination of p53 is necessary for its degradation through the proteasome (32-34). In conclusion, apoptosis mediated by a proapoptotic fibronectin fragment involves the association of p53 with ubiquitin and its subsequent degradation by the proteasome. Inhibiting either the proteolytic function of the proteasome or suppressing ubiquitin at its protein level prevented the degradation of p53 and subsequent apoptosis of these primary PDL cells. These findings provide potential therapeutic targets and strategies for addressing inflammatory diseases such as arthritis and periodontal disease that manifest alterations in the ECM.
